Articles On Acrux (ASX:ACR)

Title Source Codes Date
Hot Money Monday: Momentum trading vs investing, and how both can profit using these 3 signals

Momentum investing involves taking advantage of, and making profits from, upward trends in a stock. The strategy takes the position that the stock market’s recent winners will remain winners. Note that there is a big difference between mome...

Stockhead ACR 2 weeks ago
Regeneus trebles on back of merger deal

This week’s Bulls N’ Bears ASX Runner of the Week is… Regeneus Ltd. Its share price surged 220 per cent to join fellow movers and shakers Acrux Ltd and Perpetual Resources.

The West ACR 2 weeks ago
Acrux and TruPharma launch generic acne treatment in US market

Specialty pharmaceutical company Acrux (ASX: ACR) and its partner TruPharma have launched a generic version of Aczone 5% Gel on the US market to treat acne vulgaris. Known as Dapsone 5% Gel, the prescription topical medicine was created to...

smallcapsau.mystagingwebsite.com ACR 3 weeks ago
Guess which ASX healthcare stock is rocketing 110% on US product launch

Acrux Ltd (ASX: ACR) shares are avoiding the market weakness and rocketing higher on Wednesday. In morning trade, the ASX healthcare stock was up as much as 110% to 9.9 cents. To put that into context, a $10,000 investment yesterday aftern...

Motley Fool ACR 3 weeks ago
Top 10 at 10: Which gold miner made $125m profit last quarter?

Stockhead’s Top 10 at 10, published at ~10.40am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Stockhead ACR 3 weeks ago
Hot Money Monday: ‘Cut losses and let winners run’ – advice from legendary momentum trader Paul Tudor Jones

Momentum trading involves taking advantage of, and making profits from, upward trends in a stock. It involves betting that the stock market’s recent winners will remain winners. One of the best known momentum traders in the world is hedge f...

Stockhead ACR 1 month ago
Check Up: Big week in world of biotech after these 2 Nasdaq stocks announce breakthroughs

Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks   There were a couple of big news from the world of biotec...

Stockhead ACR 1 month ago
In Case You Missed It: US$100m manganese funding and cap raises left right and centre

Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar. Below is a wrap of the top 20 performing stocks, by percentage, that made announcements today.   ICYMI Leade...

Stockhead ACR 4 months ago
Check Up: Biden-Xi meeting could finally end opioids crisis in the US; and recent ASX biotech winners

Xi and Biden set to agree on restricting fentanyl  Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks   China’s President Xi is expected...

Stockhead ACR 5 months ago
Check Up: Why Goldman Sachs won’t change its ratings on 3 ASX stocks despite Ozempic-driven selloff

News relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD fell heavily last week But Goldman analysts say they won’t change ratings on these 3 stocks   Goldman Sachs analysts said they will make no...

Stockhead ACR 6 months ago
Dr Boreham’s Crucible: Dimerix has so far proved the doubters wrong. Next stop – the US

Ask any chief of a development-stage biotech about the prospect of a partnering or licencing deal and they will refer to a multitude of discussion with big pharma – all couched in suitably vague terms. But when Dimerix (ASX:DXB) chief Dr Ni...

Stockhead ACR 6 months ago
Check Up: How supramolecular technology is used in biotech, and why L’Oréal wants to get its hands on it

L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks   Be...

Stockhead ACR 6 months ago
Check Up: What is the FDA emergency use authorisation, and which ASX stocks were given approval?

The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks   On...

Stockhead ACR 7 months ago
ASX Biotech August Winners: Sector down despite CSL and Cochlear’s strong results, but don’t panic…

Earnings reports dominated headlines in August Despite solid results from ASX healthcare giants, the sector finished lower We take a look at which ASX healthcare stocks performed the best in August   August was all about earnings, and des...

Stockhead ACR 7 months ago
Check Up: Australian biotech sector continues to be a magnet for US investors

Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the  best and worst performing ASX biotechs over the past month   The Australian biotech sector co...

Stockhead ACR 7 months ago
Check Up: Biotech is worth ‘US$4 trillion in 10 years’, and here’s where the smart money will go

Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month   Steve Jobs used to say that the most...

Stockhead ACR 8 months ago
Dr Boreham’s Crucible: IDT Australia

Tim Boreham outlines the rise and fall of IDT Australia, and its potential revival in the cannabis and psychedelic drug market. by Tim Boreham ASX Code: ((IDT)) Share price: 6.7 cents Shares on issue: 351,337,149 Market cap: $23.5m Chief ex...

FNArena ACR 8 months ago
ASX Biotech Winners in July: Down but far from out, here’s why biotechs could stage a comeback

The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July   The Covid-19 pandemic had produced windfalls for and attracted fa...

Stockhead ACR 8 months ago
ASX July Winners: Easing inflation, AI, and an oil rally lure sidelined traders back to risky assets

The ASX was higher by around 2.5% in July The best sectors were Tech and Energy We look at the best and worst performing ASX stocks for the month For the month of July, most major indexes on the ASX rose by around 2.5%. Name % Change...

Stockhead ACR 8 months ago
CLOSING BELL: ASX falters with no US market to copy today

S&P/ASX 200 closes in the red today: -0.35%, as US stock markets enjoy a July 4 chilli dog, or something Sectors-wise, Telcos are ringing in the gainz… annnd that’s about it. Okay, Utilities are going alright  Standout stocks: Krakatoa...

Stockhead ACR 9 months ago
US FDA approves review of Acrux (ASX:ACR) nitroglycerin ointment

Acrux (ACR) receives approval from the US FDA to review a generic version of its nitroglycerin ointment at 0.4 per cent concentration The company applied for an abbreviated new drug application for the generic version, if approved by the...

themarketherald.com.au ACR 9 months ago
Check Up: Brisbane based Vaxxas set to disrupt market with game-changing, needle-free vaccines

Brisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “game changer” We look at the best and worst performing ASX biotechs over the past month   The world is anticipating a “game changer” as Brisba...

Stockhead ACR 10 months ago
Check Up: Here’s the handful of ASX small cap health stocks that actually pay dividends

Small cap health stocks are not known to pay dividends But there’s a handful of such stocks on the ASX that do pay dividends We look at the best and worst performing ASX biotechs over the past week   When we talk about dividend-paying hea...

Stockhead ACR 10 months ago
Dr Boreham’s Crucible: Dimerix

By Tim Boreham ASX code: ((DXB)) Share price: 7.0c Shares on issue: 320,748,666* Market cap: $22.5m Chief executive officer: Dr Nina Webster Board: Hugh Alsop (chair), Dr Webster, Dr Sonia Poli, Clinton Snow Financials (March quarter 2023):...

FNArena ACR 10 months ago
ASX Biotech Winners in May: We’re finally seeing signs of life on the back of another clinical breakthrough

Biotech is making a comeback in 2023 There’s been a couple of breakthroughs on the ASX this year We take a look at the ASX biotech winners in May   There are clear signs the biotech sector is springing back to life after a disappointing 2...

Stockhead ACR 10 months ago
Check Up: Here’s how diabetes drugs can help you get off the beers and lose weight

Pfizer said its diabetes drug works as well as Ozempic for weight loss What are the side effects of these weight loss drugs? Best and worst performing ASX biotechs over the past week   Earlier this week, Pfizer surprised the market by say...

Stockhead ACR 10 months ago
Check Up Budget Edition: Which ASX healthcare stocks will reap benefits from the Budget?

The Federal Budget delivers billions of dollars funding into healthcare and aged care Mental health and Telehealth also received significant funding allocations Here are the ASX stocks that could benefit   Medicare, telehealth and mental...

Stockhead ACR 11 months ago
Check Up: Healthcare is ripe for AI disruption, and Telix Pharma’s first $100m quarterly sales

Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million   Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s...

Stockhead ACR 11 months ago
Check Up: The FDA refuses to give CBD a green light, but market doesn’t seem to care

The FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have grown exponentially in the marketplace We take a look at what it all means for the cannabis industry   The US FDA announced last week that:...

Stockhead ACR 1 year ago
Acrux (ASX:ACR) announces buyout of future Lenzetto royalties

Acrux (ACR) reaches agreement for EUR 4.10 million (A$6.41 million) buyout of future Lenzetto royalties Lenzetto is used to treat oestrogen deficiency symptoms in postmenopausal women Acrux CEO and MD Michael Kotsanis said the deal im...

themarketherald.com.au ACR 1 year ago
Check Up: Japan’s startup OUI wants to halve the world’s blindness with its smartphone device

Japanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based device Which ASX healthcare companies also have smartphone-based products? A quick look at the best and worst ASX healthcare stocks over the past...

Stockhead ACR 1 year ago
Acrux (ASX:ACR) launches prilocaine and lidocaine cream in US

Acrux (ACR) and its partner, Padagis, launch a prilocaine and lidocaine cream product in the United StatesThe cream is used as a topical anaesthetic on the skin for numbing or as a pre-treatment for infiltration anaesthesiaThe company says...

themarketherald.com.au ACR 1 year ago
Australian market closes in green; utilities leads gains

Highlights The ASX 200 benchmark index closed in the green today (21 December), gaining 90.80 points or 1.29% to end at 7,115.10 points. Over the last five days, the index has lost 1.88% and 3.26% over the last 52 weeks. Utilities was...

Kalkine Media ACR 1 year ago
How out of favour Biotech has a PR problem and could learn from Dr Karl

ASX health stocks have been out of favour this year with rotation away from growth to value sector Morgan’s Scott Power said a lot of biotechs aren’t able to convert their complex science into layman’s terms Hot money going to lithium and...

Stockhead ACR 1 year ago
CLOSING BELL: No, you haven’t hit your head… HIQ is up 75% today because it’s off to play in the Premier League

ASX 200 bounces back to grind out a 0.47% win for the day HitIQ’s new deals look set to cement its place in professional sports Star gets some heartburn-inducing mail from regulators in Queensland If you’re like me and can’t read the word...

Stockhead ACR 1 year ago
Closing Bell: How to catch a falling Star, a novel by The Honourable Robert Gotterson AO

Benchmark finishes up after fierce struggle for buoyancy Absolutely no one shocked to learn Star’s worn out its welcome in QLD A solid arvo by little league miners was a well-timed boost It’s been a somewhat indecisive day for Aussie mark...

Stockhead ACR 1 year ago
Check Up: Blood clots are a $55bn opportunity and these 2 ASX stocks are vying for a slice

Blood clot programs have taken the spotlight recently as new discoveries made Two ASX health stocks are in the blood clot space Top performing ASX healthcare stocks in the past month Blood clots were top of biotech news this week after re...

Stockhead ACR 1 year ago
CLOSING BELL: How to bank $1.5bn doing sweet bugger all on your arse in a deck chair

Queen Elizabeth II soared off into the heavens Classic Minerals pulls off an amazing impersonation of Her Maj MinRes does absolutely nothing, but banks $1.5bn in value anyway   What a cracker of a day. This morning was an absolute rager,...

Stockhead ACR 1 year ago
ASX Health Stocks: Acrux and Lumos await potential approvals from the US FDA

Acrux and Lumos are waiting for FDA’s approvals Paradigm will present Phase 2 results Neuren commences Phase 2 trials Acrux (ASX:ACR) says the FDA has accepted its application for a generic version of coldsore treatment, ‘Acyclovir Cream,...

Stockhead ACR 1 year ago
Check Up: US FDA approves first clinical trial of naturally derived psychedelic drugs

US FDA approves the first clinical trial using naturally derived psychedelic drugs It could open possibilities for other clinical trials to follow suit Best and worst biotechs over the past month In a ground-breaking development, the US F...

Stockhead ACR 1 year ago
Check Up: These biotech themes got billions in VC funding. These ASX stocks could benefit

A recent research reveals which biotech segments VCs are ploughing billions of dollars into We list the ASX companies that are operating within those thematics We also list the best and worst ASX biotech performers over the past week and m...

Stockhead ACR 1 year ago
Acrux (ASX:ACR) signs commercial agreement with Padagis

Pharmaceutical company Acrux (ACR) enters an exclusive commercial agreement with US-based Padagis for one of its products Under the agreement, Padagis will commercialise Acrux’s product and will be responsible for sales, distribution and c...

themarketherald.com.au ACR 1 year ago
ASX Health Stocks: Antisense says ATL1102 could be effective in rare genetic muscle disease

Antisense announces positive study of ATL1102 Acrux to launch a new product in the US MedAdvisor gets new CEO  Antisense Therapeutics (ASX:ANP) announced a successful study into a new muscle disease indication for its lead drug, ATL1102....

Stockhead ACR 1 year ago
Firebrick Pharma (ASX:FRE) secures Malaysian patent for nasal spray

Highlights Firebrick secures patent in Malaysia for Nasodine® Nasal Spray as a treatment and preventative for common cold Nasodine is now protected in 26 countries, with China, Singapore, Japan, and Canada on the pending list Nasodine...

Kalkine Media ACR 1 year ago
Check Up: Money managers are still bullish on Healthcare; here’s what they said

The Healthcare sector has been struggling as the pandemic wanes But most money managers are still bullish on the sector The biggest movements and news from ASX healthcare stocks this week  Dr Anthony Faucci, America’s top infectious disea...

Stockhead ACR 1 year ago
Check Up: Biotechs are going through a rough patch, but recent ASX IPOs haven’t flopped too badly

The healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak market appetite  A snapshot of the return of recent ASX Healthcare IPO stocks We are currently in the longest and steepest bear market for biot...

Stockhead ACR 2 years ago
Check Up: More clinical trials and FDA funding boost. Is this the end of biotech’s woes?

Biotech sector has had a tough time recently But there are signs of things improving this year A look at biotech movers on the ASX in the past fortnight Biotech stocks entered a bear phase in the middle of 2021, and things haven’t improve...

Stockhead ACR 2 years ago
Dr Boreham’s Crucible: Mayne focuses on razzle-dazzle as oral contraceptive approaches the stage

When it comes to analysing company results, interpretations can differ as widely as Russian news agent Pravda’s reporting of the Ukraine conflict relative to the Kyiv Independent’s. Take the reformed generic drug house Mayne Pharma (ASX:MYX...

Stockhead ACR 2 years ago
Check Up: The future of telehealth, and the best and worst performing ASX health stocks for the month

Telehealth was already a growing space even before the pandemic, but COVID had launched it into the mainstream. At the height of the pandemic in 2020, data from Research and Markets showed that 76% of hospitals in the US were using teleheal...

Stockhead ACR 2 years ago
Check Up: Johnson & Johnson manoeuvre causes a stir, as CSL pulls Healthcare higher on the ASX

The ongoing lawsuit involving Johnson & Johnson (J&J)’s talc products took a controversial turn in the courts this week. The healthcare giant is currently staring down 38,000 claims that its talc products (including the famous baby...

Stockhead ACR 2 years ago